88 related articles for article (PubMed ID: 18524994)
1. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
Coluccia AM; Cirulli T; Neri P; Mangieri D; Colanardi MC; Gnoni A; Di Renzo N; Dammacco F; Tassone P; Ribatti D; Gambacorti-Passerini C; Vacca A
Blood; 2008 Aug; 112(4):1346-56. PubMed ID: 18524994
[TBL] [Abstract][Full Text] [Related]
2. Targeting SRC in mucinous ovarian carcinoma.
Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo J; Logothetis C
Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
[TBL] [Abstract][Full Text] [Related]
4. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
Wölfl M; Schwinn S; Yoo YE; Reß ML; Braun M; Chopra M; Schreiber SC; Ayala VI; Ohlen C; Eyrich M; Beilhack A; Schlegel PG
Blood; 2013 Aug; 122(7):1203-13. PubMed ID: 23836556
[TBL] [Abstract][Full Text] [Related]
5. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.
Kurebayashi J; Kanomata N; Moriya T; Kozuka Y; Watanabe M; Sonoo H
BMC Cancer; 2010 Oct; 10():568. PubMed ID: 20959018
[TBL] [Abstract][Full Text] [Related]
6. Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer.
Nobis M; McGhee EJ; Morton JP; Schwarz JP; Karim SA; Quinn J; Edward M; Campbell AD; McGarry LC; Evans TR; Brunton VG; Frame MC; Carragher NO; Wang Y; Sansom OJ; Timpson P; Anderson KI
Cancer Res; 2013 Aug; 73(15):4674-86. PubMed ID: 23749641
[TBL] [Abstract][Full Text] [Related]
7. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Ahluwalia MS; de Groot J; Liu WM; Gladson CL
Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging.
Nobis M; McGhee EJ; Herrmann D; Magenau A; Morton JP; Anderson KI; Timpson P
Cell Adh Migr; 2014; 8(5):478-86. PubMed ID: 25482620
[TBL] [Abstract][Full Text] [Related]
9. Current status of SRC inhibitors in solid tumor malignancies.
Puls LN; Eadens M; Messersmith W
Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
[TBL] [Abstract][Full Text] [Related]
10. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer.
Wen W; Han ES; Dellinger TH; Lu LX; Wu J; Jove R; Yim JH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32927828
[TBL] [Abstract][Full Text] [Related]
12. Corneal Vascularization Associated With a Novel PDGFRB Variant.
Gladkauskas T; Bruland O; Abu Safieh L; Edward DP; Rødahl E; Bredrup C
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):9. PubMed ID: 37934158
[TBL] [Abstract][Full Text] [Related]
13. In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases.
Paramashivam SK; Elayaperumal K; Natarajan BB; Ramamoorthy MD; Balasubramanian S; Dhiraviam KN
Bioinformation; 2015; 11(2):73-84. PubMed ID: 25848167
[TBL] [Abstract][Full Text] [Related]
14. New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.
Gertz MA
Leuk Lymphoma; 2008 Dec; 49(12):2240-5. PubMed ID: 19052970
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells.
Thouverey C; Apostolides P; Brun J; Caverzasio J; Ferrari S
JCI Insight; 2024 May; 9(10):. PubMed ID: 38713511
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa.
Assi A; Farhat M; Hachem MCR; Zalaquett Z; Aoun M; Daher M; Sebaaly A; Kourie HR
J Bone Oncol; 2023 Dec; 43():100511. PubMed ID: 38058514
[TBL] [Abstract][Full Text] [Related]
17. Anti-Angiogenic Activity of Drugs in Multiple Myeloma.
Saltarella I; Altamura C; Campanale C; Laghetti P; Vacca A; Frassanito MA; Desaphy JF
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046651
[TBL] [Abstract][Full Text] [Related]
18. Allosteric Inhibition of c-Abl to Induce Unfolded Protein Response and Cell Death in Multiple Myeloma.
Kosako H; Yamashita Y; Morita S; Iwabuchi S; Hashimoto S; Matsuoka TA; Sonoki T; Tamura S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555805
[TBL] [Abstract][Full Text] [Related]
19. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
Chakraborty C; Mukherjee S
Curr Oncol; 2022 Dec; 29(12):9535-9549. PubMed ID: 36547163
[TBL] [Abstract][Full Text] [Related]
20. Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance.
Melaccio A; Reale A; Saltarella I; Desantis V; Lamanuzzi A; Cicco S; Frassanito MA; Vacca A; Ria R
J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
